HEM Pharma Inc. Logo

HEM Pharma Inc.

Microbiome biotech using analysis for personalized probiotics, LBPs, and full CDMO services.

376270 | KO

Overview

Corporate Details

ISIN(s):
KR7376270005
LEI:
Country:
South Korea
Address:
경기도 수원시 영통구 창룡대로256번길 50 711호, 수원시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

HEM Pharma Inc. is a biotechnology company specializing in human microbiome research and technology. The company develops personalized healthcare solutions, probiotics, health functional foods, and Live Biotherapeutic Products (LBPs). Its core competency lies in its proprietary Personalized Microbiome Analysis System (PMAS), a screening platform used to identify and develop customized microbial solutions based on multi-omics and metabolome analysis. HEM Pharma also utilizes its MBR high-concentration fermentation technology for efficient production and offers Contract Development and Manufacturing Organization (CDMO) services through its GMP-certified facilities, supporting the entire lifecycle of microbiome-based products from research to manufacturing.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-26 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.5 MB
2025-06-26 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-06-18 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-05-21 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.4 MB
2025-05-08 00:00
Post-Annual General Meeting Information
임시주주총회결과
Korean 4.9 KB
2025-04-23 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 62.3 KB
2025-04-03 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.8 KB
2025-03-31 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 11.5 KB
2025-03-31 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 16.2 KB
2025-03-31 00:00
Regulatory News Service
본점소재지변경
Korean 5.3 KB
2025-03-31 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 6.2 KB
2025-03-31 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.1 KB
2025-03-31 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 31.0 KB
2025-03-31 00:00
Regulatory News Service
[기재정정]신규시설투자등
Korean 12.1 KB
2025-03-21 00:00
Audit Report / Information
감사보고서제출
Korean 19.1 KB

Automate Your Workflow. Get a real-time feed of all HEM Pharma Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for HEM Pharma Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for HEM Pharma Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Lexaria Bioscience Corp. Logo
Biotech firm with patented technology improving oral drug delivery and absorption.
United States of America
LEXX
Lexeo Therapeutics, Inc. Logo
Develops AAV gene therapies for genetic cardiovascular and Alzheimer's diseases.
United States of America
LXEO
LEXICON PHARMACEUTICALS, INC. Logo
Develops gene-based drugs for chronic diseases, including treatments for heart failure.
United States of America
LXRX
LIFECORE BIOMEDICAL, INC. \DE\ Logo
A CDMO for parenteral drugs, producing injectable-grade sodium hyaluronate (HA).
United States of America
LFCR
Liminatus Pharma, Inc. Logo
Clinical-stage immuno-oncology firm developing cancer therapies targeting the CD47 checkpoint.
United States of America
LIMN
Lineage Cell Therapeutics Inc. Logo
Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.
Israel
LCTX
Lipigon Pharmaceuticals AB Logo
Develops novel drugs for lipid metabolism disorders to reduce cardiovascular disease risk.
Sweden
LPGO
Lipocine Inc. Logo
Biopharma developing oral drugs for metabolic & endocrine disorders using delivery technology.
United States of America
LPCN
Lipum AB Logo
Develops first-in-class antibody treatments for chronic inflammatory diseases like arthritis.
Sweden
LIPUM
Liquidia Corp Logo
Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.
United States of America
LQDA

Talk to a Data Expert

Have a question? We'll get back to you promptly.